As of the latest Form 4 filed Aug 13, 2025.
What Biovie Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Newest filing first — the 15 most recent filings for BIVI.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2025-08-13 | 2025-08-07 | DO CUONG V President & CEO | PPurchase | +5.00K | — | — | No | Form 4 ↗ |
| 2025-01-07 | 2024-11-20 | ROGICH SIGMUND Director | AAward | +32.7K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-01-07 | 2024-11-20 | BERMAN RICHARD J Director | AAward | +34.2K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2024-07-12 | 2024-06-24 | Palumbo Joseph M Chief Medical Officer | FTax | −29.0K | $0.47 | $13.7K | No | Form 4 ↗ |
| 2024-07-12 | 2024-06-24 | Palumbo Joseph M, Chief Medical Officer | AAward | +116K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2024-07-12 | 2024-06-24 | KIM JOANNE WENDY Chief Financial Officer | FTax | −18.3K | $0.47 | $8.65K | No | Form 4 ↗ |
| 2024-07-12 | 2024-06-24 | KIM JOANNE WENDY, Chief Financial Officer | AAward | +73.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2024-07-12 | 2024-06-24 | DO CUONG V President & CEO | FTax | −42.0K | $0.47 | $19.9K | No | Form 4 ↗ |
| 2024-07-12 | 2024-06-24 | DO CUONG V, President & CEO | AAward | +168K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2024-07-12 | 2024-02-15 | Palumbo Joseph M Chief Medical Officer | FTax | −2.48K | $1.18 | $2.92K | No | Form 4 ↗ |
| 2024-07-12 | 2024-02-15 | KIM JOANNE WENDY Chief Financial Officer | FTax | −2.48K | $1.18 | $2.92K | No | Form 4 ↗ |
| 2024-07-12 | 2024-02-15 | DO CUONG V President & CEO | FTax | −4.95K | $1.18 | $5.84K | No | Form 4 ↗ |
| 2024-07-12 | 2023-02-16 | Palumbo Joseph M Chief Medical Officer | FTax | −2.48K | $5.51 | $13.6K | No | Form 4 ↗ |
| 2024-07-12 | 2023-02-16 | KIM JOANNE WENDY Chief Financial Officer | FTax | −2.48K | $5.51 | $13.6K | No | Form 4 ↗ |
| 2024-07-12 | 2023-02-16 | DO CUONG V President & CEO | FTax | −4.95K | $5.51 | $27.3K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also BIVI’s full analysis or the market-wide insider trading feed. The tabs above jump to BIVI’s other SEC data.
Source: SEC Form 4 filings for BIVI, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.